BioSpace News Archive

Nine out of ten patients with lower leg injuries prefer using an orthotic device to traditional underarm crutches, according to the first comparative medical study of its kind.

Covanos, Inc., an Atlanta-based private medical technology company, was named the Platinum Winner of the AMP’D Arena Pitch Competition at the 2019 Medical Innovation Summit, organized by Cleveland Clinic and co-sponsored by the Wallace H. Coulter Foundation.

RiceBran Technologies (NASDAQ: RIBT) (the “Company” or “RBT”), a global leader in the production and marketing of value-added products derived from rice bran and a producer of rice, rice co-product, and barley and oat products, today announced that Mr. Brent Rystrom, Chief Executive Officer & President of RBT, will host a conference call on Thursday, November 7th at 4:30 p.m.

Corcept Therapeutics Incorporated announced it will report third quarter financial results and provide a corporate update on November 7, 2019.

The first and only company in Israel to successfully complete a European regulation audit towards receiving a European EU-GMP manufacturing standard which enables export of pharmaceutical

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it will report third quarter 2019 financial results after the U.S. financial markets close on Thursday, November 7, 2019.

Animal model for the study of Chronic Myocardial Infarction indicates, for the first time, regenerative potential in a pig’s heart using uncultured autologous adipose-derived regenerative cells prepared at point of care.

Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced that the Company will participate in the following conferences in November

The VHL Alliance (VHLA) today announced the 2019 recipients of the VHLA Competitive Research Grant Program.

Positive top-line study results show that both doses of RINVOQ™ (upadacitinib; 15 mg and 30 mg, once daily) met the primary endpoint of ACR20 response in adult patients with active psoriatic arthritis who had an inadequate response to other bDMARDs at week 12 versus placebo